Can a targeted antibody-drug combo tackle rare bladder cancers?

NCT ID NCT05756569

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This phase II trial is testing whether combining enfortumab vedotin—a drug that delivers a cancer-killing agent directly to tumor cells—with the immunotherapy pembrolizumab can shrink tumors in people with locally advanced or metastatic bladder cancer of variant histology. These are less common types of bladder cancer that have spread beyond the bladder. The study enrolls about 25 adults and measures how many patients respond to the treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enfortumab vedotin plus pembrolizumab
What this could lead to: If it works, this combination could offer a new treatment option for people with less common types of bladder cancer that have spread.
What could go wrong: This is an early-phase, single-arm trial with only 25 participants, so results may not apply broadly. Side effects from the drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder adenocarcinoma bladder squamous cell carcinoma bladder urachal adenocarcinoma malignant renal pelvis neoplasm stage IVb bladder cancer ureter cancer urethra cancer urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER ADENOCARCINOMA BLADDER SQUAMOUS CELL CARCINOMA LOCALLY ADVANCED BLADDER CARCINOMA MALIGNANT RENAL PELVIS NEOPLASM MALIGNANT URETER NEOPLASM MALIGNANT URETHRAL NEOPLASM METASTATIC BLADDER CARCINOMA STAGE III BLADDER CANCER AJCC V8 STAGE IV BLADDER CANCER AJCC V8 UNRESECTABLE BLADDER CARCINOMA URACHAL ADENOCARCINOMA

Contacts and locations

Locations

Emory Saint Joseph's Hospital
RECRUITING

Atlanta, Georgia, 30342, United States
Emory University Hospital Midtown
RECRUITING

Atlanta, Georgia, 30308, United States
Emory University Hospital/Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States
Grady Health System
RECRUITING

Atlanta, Georgia, 30303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.